Cost-effectiveness of a Tobacco Cessation Care Service in the Community Pharmacy

NCT05461066 | Completed

• 1 other identifier: EPA-13-16
• Study Type: interventional
• Target: 800
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study was a non-randomized controlled trial of 12-months' follow-up with 182 Spanish community pharmacists. Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours. The control group received the usual care. Data were self-reported and collected in a computerized health registration system. Outcomes were smoking cessation and quality of life (EuroQOL-5D) collected at baseline, 6 months', and 12 months' follow-up. Cost data were collected for the study period and included direct health costs, sick leave, and intervention costs. Smoking cessation was analysed through logistic regression models. Generalized linear models were carried out for quality-adjusted life year costs. Incremental cost-effectiveness ratios (ICERs) and cost-utility ratios (RCUI) were calculated. Sensitivity analyses were performed.

Conditions

Smoking Cessation; Pharmacist-Patient Relations

Outcome Measures

Primary Outcomes (4)

• Smoking cessation

  Dichotomicus variable (yes/no)

  Before/after the intervention (1 year)

• Quality of Life (EuroQOL-5D)

  Measured with EuroQOL-5D

  1 year

• Cost-effectiveness

  In cost-effectiveness, the deterministic Incremental Cost Effectiveness Ratio (ICER) is the coefficient resulting from dividing the difference between groups in costs by the difference in probability between groups that an additional patient will cease their smoking history.

  1 year

• Cost-utility

  For the cost-utility, the Deterministic Incremental Cost-Utility Ratio (ICUR) is the coefficient resulting from dividing the difference between groups in costs by the difference between groups in quality-adjusted life years.

  1 year

Study Arms (2)

Intervention

EXPERIMENTAL

Smoking cessation intervention in community pharmacies

Behavioral: CESAR training

Control

ACTIVE COMPARATOR

Usual care of smoking cessation in community pharmacies

Behavioral: CESAR training

Interventions

CESAR training BEHAVIORAL

Intervention community pharmacists received the CESAR training to improve their smoking cessation services, consisting of an initial interview and follow-up visits to identify obstacles and reinforce behaviours.

Control; Intervention

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• smoker over 18 years old
• consent to participate
• presence at the community pharmacy for one of three reasons (a) a medical prescription for a treatment to stop smoking, (b) a consultation about how to stop smoking, (c) asking if he/she smokes when he/she consults for associated symptoms or harm.

You may not qualify if:

• cognitive impairment
• drug uses
• pregnancy or lactation.

Sponsors & Collaborators

• Sociedad Espanola de Farmacia Clinica, Familiar y Comunitaria: lead

Related Publications (1)

• Gomez Martinez JC, Gaztelurrutia Lavesa L, Mendoza Barbero A, Plaza Zamora J, Lage Pinon M, Aguilo Juanola M, Climent Catala M, de Andres Dirube A, Garcia Moreno L, Jaraiz Magarinos I, Moral Ajado M, Sanchez Marcos N. Smoking cessation intervention in the community pharmacy: Cost-effectiveness of a non-randomized cluster-controlled trial at 12-months' follow-up. Res Social Adm Pharm. 2024 Jan;20(1):19-27. doi: 10.1016/j.sapharm.2023.09.003. Epub 2023 Sep 7.

  PMID: 37704533 DERIVED

MeSH Terms

Conditions

Smoking Cessation

Condition Hierarchy (Ancestors)

Health Behavior; Behavior

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 7, 2022
• First Posted: July 15, 2022
• Study Start: January 1, 2016
• Primary Completion: December 31, 2020
• Study Completion: July 1, 2021
• Last Updated: July 15, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share